title: Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
abstract: OBJECTIVE
  Dopamine agonists have been reported to increase the risk of cardiac valve regurgitation in patients with Parkinson's disease. However, it is unknown whether these drugs might be harmful for patients with hyperprolactinaemia (HyperPRL). The aim of the study was to evaluate whether HyperPRL patients treated with dopamine agonists had a higher prevalence of cardiac valves regurgitation than that of general population.
  
  
  METHODS
  One hundred consecutive patients (79 women, 21 men, mean age 41 +/- 13 years) with HyperPRL during treatment with cabergoline were enrolled in an observational case-control study and compared with 100 matched normal subjects (controls). Valve regurgitation was assessed by echocardiography according to the American Society of Echocardiography recommendations.
  
  
  RESULTS
  Seven HyperPRL patients (7%) and six controls (6%) had moderate (grade 3) regurgitation in any valve (p = 0.980). All were asymptomatic and had no signs of cardiac disease. Mean duration of cabergoline treatment was 67 +/- 39 months (range: 3-199 months). Mean cumulative dose of cabergoline was 279 +/- 301 mg (range: 15-1327 mg). Moderate valve regurgitation was not associated with the duration of treatment (p = 0.359), with cumulative dose of cabergoline (p = 0.173), with age (p = 0.281), with previous treatment with bromocriptine (p = 0.673) or previous adenomectomy (p = 0.497) in patients with HyperPRL.
  
  
  CONCLUSIONS
  In conclusion, treatment with cabergoline was not associated with increased prevalence of cardiac valves regurgitation in patients with HyperPRL. Mean cumulative dose of cabergoline was lower in patients with HyperPRL than that reported to be deleterious for patients with Parkinson's disease: hence, longer follow-up is necessary, particularly in patients receiving weekly doses > 3 mg.
authors.affiliation: Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. f.bogazzi@endoc.med.unipi.it
authors.forename: F
authors.initials: F
authors.lastname: Bogazzi
authors.forename: S
authors.initials: S
authors.lastname: Buralli
authors.forename: L
authors.initials: L
authors.lastname: Manetti
authors.forename: V
authors.initials: V
authors.lastname: Raffaelli
authors.forename: T
authors.initials: T
authors.lastname: Cigni
authors.forename: M
authors.initials: M
authors.lastname: Lombardi
authors.forename: F
authors.initials: F
authors.lastname: Boresi
authors.forename: S
authors.initials: S
authors.lastname: Taddei
authors.forename: A
authors.initials: A
authors.lastname: Salvetti
authors.forename: E
authors.initials: E
authors.lastname: Martino
mesh_terms: D000328:Adult; D001022:Aortic Valve Insufficiency / Q000139:chemically induced*; D000077465:Cabergoline; D016022:Case-Control Studies; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D008944:Mitral Valve Insufficiency / Q000139:chemically induced*; D012307:Risk Factors; D014262:Tricuspid Valve Insufficiency / Q000139:chemically induced*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline